Jan Werner
banner
jmwerner.bsky.social
Jan Werner
@jmwerner.bsky.social
MD, Clinician-Scientist. Neurology @UKKoeln - @UniCologne. Research focus on Neuro-Oncology, imaging and amino acid PET. Postdoc @MedUniWien
Reposted by Jan Werner
Two studies led by former #EANO President Matthias Preusser demonstrate the activity of HER3-DXd in patients with brain metastases from breast and lung cancer.
Just published back-to-back in @thelancetoncol.bsky.social:
👉 breast cancer: bit.ly/4oEN1T2
👉 lung cancer: bit.ly/3LarqUf
#TUXEDO3
October 27, 2025 at 11:45 PM
#EANO2025 Emeline Tabouret reporting on theranostic potentials in Neuro-Oncology and currently ongoing trials including #EORTC trial LUMEN-1.
Moreover several interesting targets and trials in meningioma, adult and pediatric gliomas.
October 17, 2025 at 8:11 AM
Happy to provide an overview of modern PET imaging in Neuro-Oncology at the joint EANO-EANM session #EANO2025. Use the RANO/EANO recommendations in clinical practice and apply/evaluate PET RANO 1.0 and PET RANO BM 1.0
@eanoassociation.bsky.social
@galldiks.bsky.social
@nathaliealbert.bsky.social
October 17, 2025 at 7:59 AM
Fully automated evaluation of FET PET in brain tumors presented at #EANO2025. Multicenter effort with validation of >1800 PET scans comparing automated workflow with manual evaluations. @ph-lohmann.bsky.social @fz-juelich.de @eanoassociation.bsky.social
October 17, 2025 at 7:51 AM
@mjlimfat.bsky.social closes the educational day at #EANO2025 with remarks and guidance on Pregnancy and Fertility Preservation in patients with brain tumors. @eanoassociation.bsky.social
October 16, 2025 at 4:05 PM
Reposted by Jan Werner
💡Only a few seats left for the EANO Tumor Board 2025, taking place on October 15 in Prague. Join us for interactive case-based discussions and expert insights. Registration is free for EANO members. Please register by October 3.
Learn more: www.eano.eu/eanomeetings...
September 23, 2025 at 1:00 PM
Reposted by Jan Werner
🧠 Just published in Neuro-Oncology: A comprehensive consensus review by @neuroonc.bsky.social and EANO on current management and future directions in adult #Glioblastoma care. Explore key recommendations and research priorities.
🔗 academic.oup.com/neuro-oncolo...

#NeuroOncology
August 23, 2025 at 8:17 AM
Reposted by Jan Werner
Reposted by Jan Werner
📣 New journal launch! Neuro-Oncology Pediatrics is live — an open-access journal advancing global research and care for children & young adults with brain tumors.
A joint EANO & @neuroonc.bsky.social initiative.
🔗 Read more: www.eano.eu/about/news/n...
#NeuroOncology @oxfordacademic.bsky.social
August 20, 2025 at 5:33 PM
Reposted by Jan Werner
Scientists are closing in on the ability to apply genome editing to a formidable new target: the human brain.

go.nature.com/3HCKJUy
Brain editing now ‘closer to reality’: the gene-altering tools tackling deadly disorders
Stunning results in mice herald gene-editing advances for neurological diseases.
go.nature.com
August 14, 2025 at 9:02 PM
Reposted by Jan Werner
🧠 What is #ATTRACT – and how could it improve #glioblastoma care? This video (🇩🇪 with 🇬🇧 subs) explains how we test 28 drugs on tumor cells & personalize therapy.

Made by @lbg.ac.at w/ Anna Berghoff (ATTRACT Head), @mj-mair.bsky.social (Deputy Head) & Matthias Preusser (Mentor) 🚀
youtu.be/NfxxMZ_xmF4
Die KFG ATTRACT
YouTube video by Ludwig Boltzmann Gesellschaft
youtu.be
July 30, 2025 at 4:51 PM
Reposted by Jan Werner
🧠 Just published in @thelancetoncol.bsky.social: Updated RANO and EANO recommendations on the clinical use of PET imaging in gliomas.
🔗 Read more: www.thelancet.com/journals/lan...
#NeuroOncology #Glioma #PETimaging #EANO #RANO #BrainTumor #LancetOncology
July 29, 2025 at 11:39 AM
Happy to share our collaborative Point/Counterpoint article on upfront #BRAF inhibition for adult high-grade #gliomas - a summary of the first joint SNO/EANO Young Investigators debate at #SNO2024. @marjoleingeurts.bsky.social @mjlimfat.bsky.social doi.org/10.1093/neuo...
Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas
Gliomas classified as CNS WHO grade 3 and 4 (herein referred to as HGG) are aggressive, fast-growing tumors with a poor prognosis and limited therapeutic o
doi.org
July 28, 2025 at 5:03 PM
Reposted by Jan Werner
"43% of the global burden of disease is neurological, a concerningly high number."

On #WorldBrainDay, a new letter—Brain health for all ages: a global call to action ➡️ tinyurl.com/yjvtunj3
Brain health for all ages: a global call to action
The World Federation of Neurology represents 125 member societies globally and aims to foster brain health and quality neurology worldwide. The term brain health has become an acknowledged term of cru...
tinyurl.com
July 22, 2025 at 7:40 AM
Reposted by Jan Werner
A recent publication in Journal of Clinical Oncology covers stereotactic radiosurgery in small cell lung cancer patients with 1–10 brain metastases, from a multi-institutional phase II prospective trial.
🔗 ascopubs.org/doi/10.1200/...
#NeuroOncology #Glioma #BrainMetastases #EANOessentials #medsky
Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial
PURPOSEStereotactic radiation (SRS/SRT) as opposed to whole-brain radiation (WBRT) represents the standard of care for patients with a limited number of brain metastases given the relatively favorable...
ascopubs.org
July 21, 2025 at 11:10 AM
Reposted by Jan Werner
🌍 Full text access to the PET RANO BM 1.0 criteria for response assessment of brain metastases based on amino acid PET imaging:
rdcu.be/ew8m0.
RANO criteria for response assessment of brain metastases based on amino acid PET imaging
Nature Medicine - The Response Assessment in Neuro-Oncology (RANO) group defines a standardized framework for amino acid PET imaging of brain metastases for use in clinical trials and eventually in...
rdcu.be
July 21, 2025 at 1:54 PM
Reposted by Jan Werner
👉 Recently published in Clinical Cancer Research: A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy 🔗 doi.org/10.1158/1078... #EANOessentials #NeuroOncology #BrainMetastases #brainMets #medsky
July 11, 2025 at 8:18 AM
Reposted by Jan Werner
🧠 Recently published in Cancer Cell: Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target. Read the full article: www.cell.com/cancer-cell/... #EANOessentials #NeuroOncology #MalignantBrainTumor #medulloblastoma #medsky
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target
Elp1 heterozygous LOF mutations in Sonic hedgehog medulloblastoma (MB) elevate transformation risk in granule neuron precursors through stalled differentiation, DNA replication stress, genomic instabi...
www.cell.com
July 16, 2025 at 7:05 AM
Reposted by Jan Werner
A new article addressing clinical trial enrollment of glioma patients using supervised machine learning is now available in Science Advances.
📖 Read the full article: www.science.org/doi/10.1126/...
#EANOessentials #NeuroOncology #Glioma #MachineLearning #medsky
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning
Supervised machine learning models were designed and externally validated to predict glioma therapeutic clinical trial enrollment.
www.science.org
July 17, 2025 at 9:44 AM
Reposted by Jan Werner
🧠 Recently published in Nature Cancer: Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor–ligand interactions Learn more: www.nature.com/articles/s43...

#EANOessentials #NeuroOncology #MalignantBrainTumor #PediatricBrainCancer #medsky
Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor–ligand interactions - Nature Cancer
Beck et al. conducted single-cell and spatial profiling of embryonal tumors with multilayered rosettes, finding that malignant cellular hierarchies are driven by developmental programs and specific me...
www.nature.com
June 22, 2025 at 11:52 AM
Reposted by Jan Werner
Recently published in Neuro-Oncology: Clinical, molecular and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4. 🔗 doi.org/10.1093/neuo...

#EANOessentials #NeuroOncology #glioma #medsky
Clinical, molecular and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4
AbstractBackground. Astrocytoma, isocitrate dehydrogenase-mutant, WHO grade 4 (Astro4), is a new tumor type in the 2021 WHO classification of central nervo
doi.org
June 27, 2025 at 8:34 AM
Reposted by Jan Werner
🧠 A recent EORTC - European Organisation for Research and Treatment of Cancer study highlights the availability and use of amino acid PET in patients with brain tumors. 🔗 Read the full story: link.springer.com/article/10.1...
#EANOessentials #NeuroOncology #MalignantBrainTumor #PETimaging #medsky
Availability and use of PET in patients with brain tumours – a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey - European Journal of Nuclear Medicine...
Purpose Positron emission tomography (PET) is increasingly used in neuro-oncology. However, little is known about its application across European institutions and reasons for variable implementation. ...
link.springer.com
June 30, 2025 at 5:15 PM
Reposted by Jan Werner
🧠 New EORTC survey shows PET imaging is widely available and used across European brain tumour centres.

With data from 103 centres in 20 countries, the findings support PET-based endpoints in future trials.

🔗 Find out more: www.eortc.org/blog/2025/07...

#EORTCbrain #PETImaging
July 1, 2025 at 1:18 PM